{'fraction_non_alphanumeric': 0.028925619834710745, 'fraction_numerical': 0.0371900826446281, 'mean_word_length': 5.466666666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Tc-99m Sestamibi and In-111 Pentetreotide Uptake in Metastatic Papillary Thyroid Carcinoma

Approximately 25% of metastatic and recurrent differentiated (papillary and follicular) thyroid carcinoma do not concentrate I-131 Nal. In such cases, diagnosis can be attempted with other radiopharmaceuticals. The authors present a case of recurrent papillary thyroid carcinoma that was well visualized with Tc-99m sestamibi and ln-111 pentetreotide; but only poorly visualized by I-131 Nal.